• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头颈部鳞状细胞癌中肿瘤 PD-1 配体、免疫组化研究和 F-FDG PET 纹理特征的相关性。

Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in F-FDG PET in Squamous Cell Carcinoma of the Head and Neck.

机构信息

Department of Pathology, China Medical University Hospital, Taichung, Taiwan.

Department of Radiation Oncology, China Medical University Hospital, Taichung, Taiwan.

出版信息

Sci Rep. 2018 Jan 8;8(1):105. doi: 10.1038/s41598-017-18489-2.

DOI:10.1038/s41598-017-18489-2
PMID:29311707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5758832/
Abstract

To know tumor PD-L1 expression through IHC or the FDG-PET related radiomics, we investigated the association between programmed cell death protein 1 ligand (PD-L1) expression and immunohistochemical (IHC) biomarkers or textural features of 18F-fluoro-2-deoxdeoxyglucose positron emission tomography (F-FDG PET) in 53 oropharyngeal or hypopharyngeal cancer patients who were ready to undergo radiotherapy-based treatment. Differences in textural features or biomarkers between tumors with and without PD-L1 expression were tested using a Mann-Whitney U test. The predicted values for PD-L1 expression were examined using logistic regression analysis. The mean percentages of tumor PD-L1 expression were 6.2 ± 13.5. Eighteen tumors had PD-L1 expression ≥5%, whereas 30 tumors ≥1%. Using a 5% cutoff, the p16 staining percentage and the textural index of correlation were two factors associated with PD-L1 expression. The odds ratios (ORs) were 17.00 (p = 0.028) and 0.009 (p = 0.015), respectively. When dichotomizing PD-L1 at 1%, the p16 and Ki-67 staining percentages were two predictors for PD-L1 expression with ORs of 11.41 (p = 0.035) and 757.77 (p = 0.045). p16 and Ki-67 staining percentages and several PET/CT-derived textural features can provide supplemental information to determine tumor PD-L1 expression in HNCs.

摘要

为了通过免疫组织化学(IHC)或 FDG-PET 相关的放射组学来了解肿瘤 PD-L1 的表达,我们研究了程序性死亡蛋白 1 配体(PD-L1)表达与 53 例准备接受基于放疗的治疗的口咽或下咽癌患者的免疫组织化学(IHC)生物标志物或 18F-氟-2-脱氧葡萄糖正电子发射断层扫描(F-FDG PET)纹理特征之间的关联。使用 Mann-Whitney U 检验测试 PD-L1 表达阳性和阴性肿瘤之间纹理特征或生物标志物的差异。使用逻辑回归分析检查 PD-L1 表达的预测值。肿瘤 PD-L1 表达的平均百分比为 6.2±13.5。18 个肿瘤 PD-L1 表达≥5%,30 个肿瘤 PD-L1 表达≥1%。使用 5%的截止值,p16 染色百分比和纹理相关指数是与 PD-L1 表达相关的两个因素。比值比(OR)分别为 17.00(p=0.028)和 0.009(p=0.015)。当将 PD-L1 分为 1%时,p16 和 Ki-67 染色百分比是 PD-L1 表达的两个预测因子,OR 分别为 11.41(p=0.035)和 757.77(p=0.045)。p16 和 Ki-67 染色百分比和几个 PET/CT 衍生的纹理特征可以提供补充信息,以确定 HNC 中肿瘤 PD-L1 的表达。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ba/5758832/e4c016474798/41598_2017_18489_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ba/5758832/49a9b0a3bf03/41598_2017_18489_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ba/5758832/e4c016474798/41598_2017_18489_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ba/5758832/49a9b0a3bf03/41598_2017_18489_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ba/5758832/e4c016474798/41598_2017_18489_Fig2_HTML.jpg

相似文献

1
Associations of Tumor PD-1 Ligands, Immunohistochemical Studies, and Textural Features in F-FDG PET in Squamous Cell Carcinoma of the Head and Neck.头颈部鳞状细胞癌中肿瘤 PD-1 配体、免疫组化研究和 F-FDG PET 纹理特征的相关性。
Sci Rep. 2018 Jan 8;8(1):105. doi: 10.1038/s41598-017-18489-2.
2
Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on F-fluorodeoxyglucose positron emission tomography/computed tomography.F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描显示的程序性细胞死亡配体1表达的肺癌的代谢特征
Cancer Med. 2017 Nov;6(11):2552-2561. doi: 10.1002/cam4.1215. Epub 2017 Oct 4.
3
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma.肺鳞癌中肿瘤相关免疫与 18F-FDG-PET 的相关性。
Lung Cancer. 2018 May;119:71-77. doi: 10.1016/j.lungcan.2018.03.001. Epub 2018 Mar 16.
4
Zr-DFO-Durvalumab PET/CT Before Durvalumab Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer.头颈部癌复发或转移患者在接受 durvalumab 治疗前的 Zr-DFO-Durvalumab PET/CT
J Nucl Med. 2022 Oct;63(10):1523-1530. doi: 10.2967/jnumed.121.263470. Epub 2022 May 5.
5
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.一种经验证可用于分析非小细胞肺癌和头颈部鳞状细胞癌的程序性细胞死亡配体-1免疫组织化学检测方法的开发。
Diagn Pathol. 2016 Oct 8;11(1):95. doi: 10.1186/s13000-016-0545-8.
6
Diagnostic value of F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8tumour-infiltrating lymphocytes in oral squamous cell carcinoma.氟代脱氧葡萄糖正电子发射断层扫描预测口腔鳞状细胞癌肿瘤 PD-L1 和肿瘤浸润 CD8+T 淋巴细胞定义的肿瘤免疫状态的诊断价值。
Br J Cancer. 2020 May;122(11):1686-1694. doi: 10.1038/s41416-020-0820-z. Epub 2020 Apr 2.
7
Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma.评估口咽鳞状细胞癌中的 PD-1 轴和免疫效应细胞浸润。
Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):137-145. doi: 10.1016/j.ijrobp.2018.05.002. Epub 2018 Jun 29.
8
The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).辅助放化疗后头颈癌患者的PD-1/PD-L1轴与人类乳头瘤病毒:德国癌症联盟放射肿瘤学组(DKTK-ROG)的多中心研究
Int J Cancer. 2017 Aug 1;141(3):594-603. doi: 10.1002/ijc.30770. Epub 2017 May 19.
9
Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma.头颈部鳞状细胞癌的免疫组化生物标志物及PET/CT上的FDG摄取情况
Acta Oncol. 2015;54(9):1408-15. doi: 10.3109/0284186X.2015.1062539. Epub 2015 Aug 9.
10
Association Between PD-L1 Expression and Metabolic Activity on F-FDG PET/CT in Patients with Small-sized Lung Cancer.小肺癌患者F-FDG PET/CT上PD-L1表达与代谢活性之间的关联
Anticancer Res. 2017 Dec;37(12):7073-7082. doi: 10.21873/anticanres.12180.

引用本文的文献

1
Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.头颈部鳞状细胞癌诊断与治疗中个性化医学的发展与展望。
Cancer Rep (Hoboken). 2024 Mar;7(3):e2045. doi: 10.1002/cnr2.2045.
2
A Radiomics Approach to Identify Immunologically Active Tumor in Patients with Head and Neck Squamous Cell Carcinomas.一种用于识别头颈部鳞状细胞癌患者免疫活性肿瘤的放射组学方法。
Cancers (Basel). 2023 Nov 11;15(22):5369. doi: 10.3390/cancers15225369.
3
Evaluation of Programmed Death - Ligand 1 (Pd-L1) Expression in Head and Neck Squamous Cell Carcinoma.

本文引用的文献

1
Immunohistochemical biomarkers and volumetric parameters for predicting radiotherapy-based outcomes in patients with p16-negative pharyngeal cancer.用于预测p16阴性咽癌患者基于放疗的预后的免疫组织化学生物标志物和体积参数。
Oncotarget. 2017 Aug 21;8(42):72342-72351. doi: 10.18632/oncotarget.20374. eCollection 2017 Sep 22.
2
Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.程序性死亡配体1(PD-L1)肿瘤表达与三阴性乳腺癌患者的较好预后及糖尿病疾病相关。
Int J Mol Sci. 2017 Feb 21;18(2):459. doi: 10.3390/ijms18020459.
3
头颈部鳞状细胞癌中程序性死亡配体1(Pd-L1)表达的评估
Iran J Pathol. 2023 Spring;18(2):193-201. doi: 10.30699/ijp.2023.1988955.3057. Epub 2023 Jun 20.
4
Radiomics in Hypopharyngeal Cancer Management: A State-of-the-Art Review.下咽癌管理中的影像组学:最新综述
Biomedicines. 2023 Mar 6;11(3):805. doi: 10.3390/biomedicines11030805.
5
Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians.放射组学指导的检查点抑制剂免疫治疗在癌症精准医学中的应用:临床医生的综述。
Front Immunol. 2023 Mar 1;14:1088874. doi: 10.3389/fimmu.2023.1088874. eCollection 2023.
6
Radiomics Applications in Head and Neck Tumor Imaging: A Narrative Review.放射组学在头颈部肿瘤成像中的应用:一篇综述
Cancers (Basel). 2023 Feb 12;15(4):1174. doi: 10.3390/cancers15041174.
7
Predicting PD-L1 expression status in patients with non-small cell lung cancer using [F]FDG PET/CT radiomics.使用[F]FDG PET/CT 影像组学预测非小细胞肺癌患者的 PD-L1 表达状态。
EJNMMI Res. 2023 Jan 22;13(1):4. doi: 10.1186/s13550-023-00956-9.
8
Radiomics from Various Tumour Volume Sizes for Prognosis Prediction of Head and Neck Squamous Cell Carcinoma: A Voted Ensemble Machine Learning Approach.基于不同肿瘤体积大小的头颈鳞状细胞癌预后预测的影像组学:一种投票集成机器学习方法
Life (Basel). 2022 Sep 5;12(9):1380. doi: 10.3390/life12091380.
9
Prognostic impact of an integrative analysis of [F]FDG PET parameters and infiltrating immune cell scores in lung adenocarcinoma.[F]FDG PET参数与浸润免疫细胞评分综合分析对肺腺癌的预后影响
EJNMMI Res. 2022 Jun 27;12(1):38. doi: 10.1186/s13550-022-00908-9.
10
Radiomics in Oncological PET Imaging: A Systematic Review-Part 1, Supradiaphragmatic Cancers.肿瘤PET成像中的放射组学:系统综述 - 第1部分,膈上癌症
Diagnostics (Basel). 2022 May 27;12(6):1329. doi: 10.3390/diagnostics12061329.
PD-L1 testing, fit for routine evaluation? From a pathologist's point of view.
程序性死亡配体1(PD-L1)检测,适用于常规评估吗?从病理学家的角度来看。
Memo. 2016;9(4):201-206. doi: 10.1007/s12254-016-0292-2. Epub 2016 Oct 28.
4
Correlation of pretreatment F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes.下咽癌治疗前F-FDG PET肿瘤纹理特征与基因表达的相关性及其对基于放疗的治疗结果的影响。
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):567-580. doi: 10.1007/s00259-016-3580-5. Epub 2016 Dec 20.
5
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.纳武利尤单抗用于复发性头颈部鳞状细胞癌
N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8.
6
Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery.对于适合进行 upfront 手术的非小细胞肺癌(NSCLC)患者,FDG-PET 上的代谢信息与免疫标志物组织表达的相关性。
Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1954-61. doi: 10.1007/s00259-016-3425-2. Epub 2016 Jun 1.
7
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.程序性死亡受体配体1(PD-L1)表达作为癌症免疫治疗中的预测生物标志物
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.
8
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.癌症患者对抗PD-L1抗体MPDL3280A反应的预测性相关因素。
Nature. 2014 Nov 27;515(7528):563-7. doi: 10.1038/nature14011.
9
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer.程序性死亡配体1(PD-L1)的表达与人类乳腺癌的不良预后相关。
Breast Cancer Res Treat. 2014 Jul;146(1):15-24. doi: 10.1007/s10549-014-2988-5. Epub 2014 May 20.
10
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.程序性死亡受体-1(PD-1)、PD-1配体与肿瘤免疫微环境的其他特征与抗PD-1治疗反应的相关性
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.